Recent Advances on Plasmin Inhibitors for the Treatment of Fibrinolysis-Related Disorders

Medicinal Research Reviews

Volumn 34, Issue 6, 2014, Pages 1168-1216

  Al Horani, Rami A ^a   Desai, Umesh R ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Allosteric inhibition; Aprotinin; Cyclic peptidomimetics; Glycosaminoglycan mimetics; Plasmin(ogen); Serine proteases antifibrinolytics; Tranexamic acid

Indexed keywords

4 GUANIDINOBENZOIC ACID 4 SULFAMOYLPHENYL ESTER MESYLATE; ALDEHYDE; AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; APROTININ; CHYMOTRYPSIN TRYPSIN; CUPRIC ION; CYCLOHEXANONE DERIVATIVE; DEXTRAN SULFATE; DX 1000; GABEXATE; LYSINE DERIVATIVE; NAFAMSTAT; NITRILE; PASE 535; PEPTIDOMIMETIC AGENT; PLACENTA PROTEIN 5; PLASMA KALLIKREIN; PLASMIN; PLASMIN INHIBITOR; PLASMINOGEN; POLYVINYL ALCOHOL; PROTEINASE INHIBITOR; SERINE PROTEINASE INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR 1; UNCLASSIFIED DRUG; UPAMOSTAT; YO 2; DIPEPTIDE; GUANIDINE DERIVATIVE; PASI 535; PHENYLALANINE; YO 2 COMPOUND;

ANTICOAGULATION; ARTICLE; CYCLIZATION; DRUG BIOAVAILABILITY; ENZYME INHIBITION; ENZYME SPECIFICITY; EUGLOBULIN LYSIS TEST; FIBRINOLYSIS; HUMAN; HYDROGEN BOND; NONHUMAN; PHAGE DISPLAY; PROTEIN DEGRADATION; STRUCTURE ACTIVITY RELATION; THROMBIN TIME; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS;

ANTIFIBRINOLYTIC AGENTS; APROTININ; DIPEPTIDES; DRUG DESIGN; FIBRINOLYSIN; FIBRINOLYSIS; GUANIDINES; HUMANS; PHENYLALANINE; SERINE PROTEINASE INHIBITORS;

EID: 84907972088     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21315     Document Type: Article

References (288)

1. Levy JH. Pharmacologic methods to reduce perioperative bleeding. Transfusion 2008;48:31S-38S.
2. Dhir A. Antifibrinolytics in cardiac surgery. Ann Card Anaesth 2013;16:117-125.
3. Spahn DR, Goodnough LT. Alternatives to blood transfusion. Lancet 2013;381:1855-1865.
4. Shander A, Hofmann A, Ozawa S, Theusinger OM, Gombotz H, Spahn DR. Activity-based costs of blood transfusions in surgical patients at four hospitals. Transfusion 2010;50:753-765.
5. Trudell J, McMurdy N. Current antifibrinolytic therapy for coronary artery revascularization. AANA 2008;76:121-124.
6. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 2009;145:24-33.
7. Toh CH, Dennis M. Disseminated intravascular coagulation: Old disease, new hope. BMJ 2003;327:974-977.
8. Hvas AM, Sorensen HT, Norengaard L, Christiansen K, Ingerslev J, Sorensen B. Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A. J Thromb Haemost 2007;5:2408-2414.
9. Philipp CS. Antifibrinolytics in women with menorrhagia. Thromb Res 2011;127:S113-S115.
10. Tiede A, Rand JH, Budde U, Ganser A, Federici AB. How I treat the acquired von Willebrand syndrome. Blood 2011;117:6777-6785.
11. Saupe SM, Leubner S, Betz M, Klebe G, Steinmetzer T. Development of new cyclic plasmin inhibitors with excellent potency and selectivity. J Med Chem 2013;56:820-831.
12. Henry BL, Desai UR. Anticoagulants: Drug discovery and development. In: Rotella D, Abraham DJ, Eds. Burger's Medicinal Chemistry, 7th ed. New York: John Wiley and Sons; 2010. p 365-408.
13. Anglés-Cano E. Overview on fibrinolysis: Plasminogen activation pathways on fibrin and cell surfaces. Chem Phys Lipids 1994;67-68:353-362.
14. Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982;257:2912-2919.
15. Lerch PG, Rickli EE, Lergier W, Gillessen D. Localization of individual lysine-binding regions in human plasminogen and investigations on their complex-forming properties. Eur J Biochem 1980;107:7-13.
16. Lijnen HR, Van Hoef B, Collen D. On the molecular interactions between fibrin, tissue-type plasminogen activator and plasminogen. Thromb Res Suppl 1990;10:45-54.
17. Lu BG, Sofian T, Law RH, Coughlin PB, Horvath AJ. Contribution of conserved lysine residues in the alpha2-antiplasmin C terminus to plasmin binding and inhibition. J Biol Chem 2011;286:24544-24552.
18. Tsurupa G, Yakovlev S, McKee P, Medved L. Noncovalent interaction of alpha(2)-antiplasmin with fibrin(ogen): localization of alpha(2)-antiplasmin-binding sites. Biochemistry 2010;49:7643-7651.
19. Foley JH, Kim PY, Mutch NJ, Gils A. Insights into thrombin activatable fibrinolysis inhibitor function and regulation. J Thromb Haemost 2013;(Suppl 1)11:306-315.
20. Nicholl SM, Roztocil E, Davies MG. Plasminogen activator system and vascular disease. Curr Vasc Pharmacol 2006;4:101-116.
21. Binder BR, Christ G, Gruber F, Grubic N, Hufnagl P, Krebs M, Mihaly J, Prager GW. Plasminogen activator inhibitor 1: Physiological and pathophysiological roles. News Physiol Sci 2002;17:56-61.
22. Steiner JP, Migliorini M, Strickland DK. Characterization of the reaction of plasmin with alpha 2-macroglobulin: Effect of antifibrinolytic agents. Biochemistry 1987;26:8487-8495.
23. Kunadian V, Gibson CM. Thrombolytics and myocardial infarction. Cardiovasc Ther 2012;30:e81-e88.
24. Ceruti P, Principe M, Capello M, Cappello P, Novelli F. Three are better than one: Plasminogen receptors as cancer theranostic targets. Exp Hematol Oncol 2013;2:12.
25. Kwaan HC, McMahon B. The role of plasminogen-plasmin system in cancer. Cancer Treat Res 2009;148:43-66.
26. Deryugina EI, Quigley JP. Cell surface remodeling by plasmin: A new function for an old enzyme. J Biomed Biotechnol 2012;2012:564259.
27. Schaller J, Gerber SS. The plasmin-antiplasmin system: Structural and functional aspects. Cell Mol Life Sci 2011;68:785-801.
28. Tang L, Han X. The urokinase plasminogen activator system in breast cancer invasion and metastasis. Biomed Pharmacother 2013;67:179-182.
29. Li X, Syrovets T, Genze F, Pitterle K, Oberhuber A, Orend KH, Simmet T. Plasmin triggers chemotaxis of monocyte-derived dendritic cells through an Akt2-dependent pathway and promotes a T-helper type-1 response. Arterioscler. Thromb Vasc Biol 2010;30:582-590.
30. Li Q, Laumonnier Y, Syrovets T, Simmet T. Recruitment of CCR6-expressing Th17 cells by CCL20 secreted from plasmin-stimulated macrophages. Acta Biochim Biophys Sin (Shanghai) 2013;45:593-600.
31. Rønø B, Engelholm LH, Lund LR, Hald A. Gender affects skin wound healing in plasminogen deficient mice. PLoS ONE 2013;8:e59942.
32. Kawao N, Nagai N, Okada K, Okumoto K, Ueshima S, Matsuo O. Role of plasminogen in macrophage accumulation during liver repair. Thromb Res 2010;125:e214-e221.
33. Wilkins-Port CE, Higgins SP, Higgins CE, Kobori-Hotchkiss I, Higgins PJ. Complex regulation of the pericellular proteolytic microenvironment during tumor progression and wound repair: Functional interactions between the serine protease and matrix metalloproteinase cascades. Biochem Res Int 2012;2012:454368.
34. Gutiérrez-Fernández A, Gingles NA, Bai H, Castellino FJ, Parmer RJ, Miles LA. Plasminogen enhances neuritogenesis on laminin-1. J Neurosci 2009;29:12393-12400.
35. Jacovina AT, Zhong F, Khazanova E, Lev E, Deora AB, Hajjar KA. Neuritogenesis and the nerve growth factor-induced differentiation of PC-12 cells requires annexin II-mediated plasmin generation. J Biol Chem 2001;276:49350-49358.
36. Ny A, Leonardsson G, Hägglund AC, Hägglöf P, Ploplis VA, Carmeliet P, Ny T. Ovulation in plasminogen-deficient mice. Endocrinology 1999;140:5030-5035.
37. Koizumi M, Momoeda M, Hiroi H, Nakazawa F, Nakae H, Ohno T, Yano T, Taketani Y. Inhibition of proteases involved in embryo implantation by cholesterol sulfate. Hum Reprod 2010;25:192-197.
38. Syrovets T, Simmet T. Novel aspects and new roles for the serine protease plasmin. Cell Mol Life Sci 2004;61:873-885.
39. Nakagami Y, Abe K, Nishiyama N, Matsuki N. Laminin degradation by plasmin regulates long-term potentiation. J Neurosci 2000;20:2003-2010.
40. Bonnefoy A, Legrand C. Proteolysis of subendothelial adhesive glycoproteins (fibronectin, thrombospondin, and von Willebrand factor) by plasmin, leukocyte cathepsin G, and elastase. Thromb Res 2000;98:323-332.
41. Netzel-Arnett S, Mitola DJ, Yamada SS, Chrysovergis K, Holmbeck K, Birkedal-Hansen H, Bugge TH. Collagen dissolution by keratinocytes requires cell surface plasminogen activation and matrix metalloproteinase activity. J Biol Chem 2002;277:45154-45161.
42. Lijnen HR. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 2001;86:324-333.
43. Kwaan HC, McMahon B. The role of plasminogen-plasmin system in cancer. Cancer Treat Res 2009;148:43-66.
44. Danø K, Behrendt N, Høyer-Hansen G, Johnsen M, Lund LR, Ploug M, Rømer J. Plasminogen activation and cancer. Thromb Haemost 2005;93:676-681.
45. Ritchie BC. Protease inhibitors in the treatment of hereditary angioedema. Transfus Apheresis Sci 2003;29:259-267.
46. Du-Thanh A, Raison-Peyron N, Drouet C, Guillot B. Efficacy of tranexamic acid in sporadic idiopathic bradykinin angioedema. Allergy 2010;65:793-795.
47. Syrovets T, Lunov O, Simmet, T. Plasmin as a proinflammatory cell activator. J Leukocyte Biol 2012;92:509-519.
48. Schuliga M, Westall G, Xia Y, Stewart AG. The plasminogen activation system: New targets in lung inflammation and remodeling. Curr Opin Pharmacol 2013;13:386-393.
49. Nakae H, Hiroi H, Momoeda M, Koizumi M, Iwamori M, Taketani Y. Inhibition of cell invasion and protease activity by cholesterol sulfate. Fertil Steril 2010;94:2455-2457.
50. Okada Y, Tsuda Y, Wanaka K, Tada M, Okamoto U, Okamoto S, Hijikata-Okunomiya A, Bokonyi G, Szende B, Keri G. Development of plasmin and plasma kallikrein selective inhibitors and their effect on M1 (melanoma) and HT29 cell lines. Bioorg Med Chem Lett 2000;10:2217-2221.
51. Ishihara M, Nishida C, Tashiro Y, Gritli I, Rosenkvist J, Koizumi M, Okaji Y, Yamamoto R, Yagita H, Okumura K, Nishikori M, Wanaka K, Tsuda Y, Okada Y, Nakauchi H, Heissig B, Hattori K. Plasmin inhibitor reduces T-cell lymphoid tumor growth by suppressing matrix metalloproteinase-9-dependent CD11b(+)/F4/80(+) myeloid cell recruitment. Leukemia 2012;26:332-339.
52. Swedberg JE, Harris JM. Natural and engineered plasmin inhibitors: Applications and design strategies. Chembiochem 2012;13:336-348.
53. Castellino FJ, Ploplis VA. Structure and function of the plasminogen/plasmin system. Thromb Haemost 2005;93:647-654.
54. Novokhatny V. Structure and activity of plasmin and other direct thrombolytic agents. Thromb Res 2008;122:53-58.
55. Zhang L, Seiffert D, Fowler BJ, Jenkins GR, Thinnes TC, Loskutoff DJ, Parmer RJ, Miles LA. Plasminogen has a broad extrahepatic distribution. Thromb Haemost 2002;87:493-501.
56. Ramesh V, Petros AM, Llinás M, Tulinsky A, Park CH. Proton magnetic resonance study of lysine-binding to the kringle 4 domain of human plasminogen. The structure of the binding site. J Mol Biol 1987;198:481-498.
57. Mathews II, Vanderhoff-Hanaver P, Castellino FJ, Tulinsky A. Crystal structures of the recombinant kringle 1 domain of human plasminogen in complexes with the ligands epsilon-aminocaproic acid and trans-4-(aminomethyl)cyclohexane-1-carboxylic Acid. Biochemistry 1996;35:2567-2576.
58. Sehl LC, Castellino FJ. Thermodynamic properties of the binding of alpha-, omega-amino acids to the isolated kringle 4 region of human plasminogen as determined by high sensitivity titration calorimetry. J Biol Chem 1990;265:5482-5486.
59. Menhart N, Sehl LC, Kelley RF, Castellino FJ. Construction, expression and purification of recombinant kringle 1 of human plasminogen and analysis of its interaction with omega-amino acids. Biochemistry 1991;30:1948-1957.
60. Menhart N, McCance SG, Sehl LC, Castellino FJ. Functional independence of the kringle 4 and kringle 5 regions of human plasminogen. Biochemistry 1993;32:8799-8806.
61. Menhart N, Castellino FJ. The importance of the hydrophobic components of the binding energies in the interaction of omega-amino acid ligands with isolated kringle polypeptide domains of human plasminogen. Int J Pept Protein Res 1995;46:464-470.
62. Marti DN, Schaller J, Llinas M. Solution structure and dynamics of the plasminogen kringle 2-AMCHA complex: 3(1)-Helix in homologous domains. Biochemistry 1999;38:15741-15755.
63. Urano T, Chibber BAK, Castellino FJ. The reciprocal effects of ε-aminohexanoic acid and chloride ion on the activation of human [Glu1]plasminogen by human urokinase. Proc Natl Acad Sci USA 1987;84:4031-4034.
64. Lucas MA, Fretto LJ, McKee PA. The binding of human plasminogen to fibrin and fibrinogen. J Biol Chem 1983;258:4249-4256.
65. Kim PY, Tieu LD, Stafford AR, Fredenburgh JC, Weitz JI. A high affinity interaction of plasminogen with fibrin is not essential for efficient activation by tissue-type plasminogen activator. J Biol Chem 2012;287:4652-4661.
66. Sanderson-Smith ML, Dowton M, Ranson M, Walker MJ. The plasminogen-binding group A streptococcal M protein-related protein Prp binds plasminogen via arginine and histidine residues. J Bacteriol 2007;189:1435-1440.
67. Fulde M, Rohde M, Polok A, Preissner KT, Chhatwal GS, Bergmann S. Cooperative plasminogen recruitment to the surface of Streptococcus canis via M protein and enolase enhances bacterial survival. MBio 2013;4:e00629-e00612.
68. Wang H, Doll JA, Jiang K, Cundiff DL, Czarnecki JS, Wilson M, Ridge KM, Soff GA. Differential binding of plasminogen, plasmin, and angiostatin4.5 to cell surface beta-actin: Implications for cancer-mediated angiogenesis. Cancer Res 2006;66:7211-7215.
69. Plow EF, Herren T, Redlitz A, Miles LA, Hoover-Plow JL. The cell biology of the plasminogen system. FASEB J 1995;9:939-945.
70. Bürgin J, Schaller J. Expression, isolation and characterization of a mutated human plasminogen kringle 3 with a functional lysine binding site. Cell Mol Life Sci 1999;55:135-141.
71. Wang X, Lin X, Loy JA, Tang J, Zhang XC. Crystal structure of the catalytic domain of human plasmin complexed with streptokinase. Science 1998, 281:1662-1665.
72. Anonick PK, Vasudevan J, Gonias SL. Antifibrinolytic activities of alpha-N-acetyl-L-lysine methyl ester, epsilon-aminocaproic acid, and tranexamic acid. Importance of kringle interactions and active site inhibition. Arterioscler Thromb 1992;12:708-716.
73. Tordai H, Bányai L, Patthy L. The PAN module: The N-terminal domains of plasminogen and hepatocyte growth factor are homologous with the apple domains of the prekallikrein family and with a novel domain found in numerous nematode proteins. FEBS Lett 1999;461:63-67.
74. Xue Y, Bodin C, Olsson K. Crystal structure of the native plasminogen reveals an activation-resistant compact conformation. J Thromb Haemost 2012;10:1385-1396.
75. Law RH, Caradoc-Davies T, Cowieson N, Horvath AJ, Quek AJ, Encarnacao JA, Steer D, Cowan A, Zhang Q, Lu BG, Pike RN, Smith AI, Coughlin PB, Whisstock JC. The X-ray crystal structure of full-length human plasminogen. Cell Rep 2012;1:185-190.
76. Robbins KC, Summaria L, Hsieh B, Shah RJ. The peptide chains of human plasmin. Mechanism of activation of human plasminogen to plasmin. J Biol Chem 1967;242:2333-2342.
77. Harris JL, Backes BJ, Leonetti F, Mahrus S, Ellman JA, Craik CS. Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries. Proc Natl Acad Sci USA 2000;97:7754-7759.
78. Backes BJ, Harris JL, Leonetti F, Craik CS, Ellman JA. Synthesis of positional-scanning libraries of fluorogenic peptide substrates to define the extended substrate specificity of plasmin and thrombin. Nat Biotechnol 2000;18:187-193.
79. Gosalia DN, Salisbury CM, Maly DJ, Ellman JA, Diamond SL. Profiling serine protease substrate specificity with solution phase fluorogenic peptide microarrays. Proteomics 2005;5:1292-1298.
80. Swedberg JE, Harris JM. Plasmin substrate binding site cooperativity guides the design of potent peptide aldehyde inhibitors. Biochemistry 2011;50:8454-8462.
81. Rawlings ND, Barrett AJ, Bateman A. MEROPS: The peptidase database. Nucleic Acids Res 2010;38:D227-D233.
82. Xia VW, Steadman RH. Antifibrinolytics in orthotopic liver transplantation: current status and controversies. Liver Transpl 2005;11:10-18.
83. Ortmann E, Besser MW, Klein AA. Antifibrinolytic agents in current anaesthetic practice. Br J Anaesth 2013;111:549-563.
84. Alkozai EM, Lisman T, Porte RJ. Bleeding in liver surgery: Prevention and treatment. Clin Liver Dis 2009;13:145-154.
85. Tiede A. Diagnosis and treatment of acquired von Willebrand syndrome. Thromb Res 2012;130(Suppl 2):S2-S6.
86. Okamoto S. Plasmin and antiplasmin: Their pathologic physiology. Keio J Med 1959;8:211-217.
87. Okamoto S, Sato S, Takada Y, Okamoto U. An active stereo-isomer (trans-form) of AMCHA and its antifibrinolytic (antiplasminic) action in vitro and in vivo. Keio J Med 1964;13:177-185.
88. Okamoto S, Hijikata A. Rational approach to proteinase inhibitors. In: Ariens EJ, Ed. Medicinal Chemistry: A Series of Monographs, Vol. 11. Drug Design: Parts 1-10. MA, USA: Academic Press, Inc; 1975. p 143-169.
89. Markwardt F. Synthetic inhibitors of fibrinolysis. In: Markwardt F, Ed. Handbook of Experimental Pahramcology: Fibrinolytics and Anti-fibrinolytics, Vol. 46. Berlin: Springer; 1978. p 511-577.
90. Royston D. Blood-sparing drugs: Aprotinin, tranexamic acid, and epsilon-aminocaproic acid. Int Anesthesiol Clin 1995;33:155-179.
91. Makhija N, Sarupria A, Kumar Choudhary S, Das S, Lakshmy R, Kiran U. Comparison of epsilon aminocaproic acid and tranexamic acid in thoracic aortic surgery: Clinical efficacy and safety. J Cardiothorac Vasc Anesth 2013;27:1201-1207.
92. Lecker I, Wang DS, Romaschin AD, Peterson M, Mazer CD, Orser BA. Tranexamic acid concentrations associated with human seizures inhibit glycine receptors. J Clin Invest 2012;122:4654-4666.
93. Lukes AS, Kouides PA, Moore KA. Tranexamic acid: A novel oral formulation for the treatment of heavy menstrual bleeding. Womens Health (Lond Engl) 2011;7:151-158.
94. Midura-Nowaczek K, Purwin M, Markowska A, Drozdowska D, Bruzgo M. Effect of short peptides containing lysine and epsilon-aminocaproic acid on fibrinolytic activity of plasmin and topoisomerase II action on supercoiled DNA. Acta Pol Pharm 2013;70:431-434.
95. Purwin M, Bruzgo I, Markowska A, Midura-Nowaczek K. Short peptides containing L-lysine and epsilon-aminocaproic acid as potential plasmin inhibitors. Pharmazie 2009;64:765-767.
96. Midura-Nowaczek K, Lepietuszko I, Bruzgo I. Synthesis of alkylamides of dipeptides as potential plasmin inhibitors. Acta Pol Pharm 2006;63:33-37.
97. Midura-Nowaczek K, Roszkowska-Jakimiec W, Lepietuszko I, Bruzgo I. Synthesis of benzylamides of dipeptides as potential inhibitors of plasmin. Pharmazie 2003;58:687-689.
98. Midura-Nowaczek K, Bruzgo I, Roszkowska-Jakimiec W, Worowski K. Synthesis and activity of dipeptides containing epsilon-aminocaproic acid. Acta Pol Pharm 1994;51:499-504.
99. Midura-Nowaczek K, Bruzgo I, Roszkowska-Jakimiec W, Worowski K. Synthesis and activity of N epsilon-aminocaproyl-L-norleucine derivatives. Acta Pol Pharm 1996;53:221-223.
100. Bruzgo I, Midura-Nowaczek K, Bruzgo M, Kaczyńska J, Roszkowska-Jakimiec W. Effect of epsilon-aminocaproylamino acids on fibrin formation. Acta Pol Pharm 2006;63:149-152.
101. Boström J, Grant JA, Fjellström O, Thelin A, Gustafsson D. Potent fibrinolysis inhibitor discovered by shape and electrostatic complementarity to the drug tranexamic acid. J Med Chem 2013;56:3273-3280.
102. Karaman R, Ghareeb H, Dajani KK, Scrano L, Hallak H, Abu-Lafi S, Mecca G, Bufo SA. Design, synthesis and in vitro kinetic study of tranexamic acid prodrugs for the treatment of bleeding conditions. J Comput Aided Mol Des 2013;27:615-635.
103. Zerangue N, Jandeleit B, Li Y, Gallop MA. Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use. US Patent Application US20100036148 A1, 2010.
104. Okada Y, Tsuda Y, Teno N, Wanaka K, Bohgaki M, Hijikata-Okunomiya A, Naito T, Okamoto S. Synthesis of active center-directed peptide inhibitors of plasmin. Chem Pharm Bull (Tokyo) 1988;36:1289-1297.
105. Tsuda Y, Teno N, Okada Y, Wanaka K, Bohgaki M, Hijikata-Okunomiya A, Okamoto U, Naito T, Okamoto S. Synthesis of tripeptide chloromethyl ketones and examination of their inhibitory effects on plasmin and plasma kallikrein. Chem Pharm Bull (Tokyo) 1989;37:3108-3111.
106. Teno N, Wanaka K, Okada Y, Tsuda Y, Okamoto U, Hijikata-Okunomiya A, Naito T, Okamoto S. Development of active center-directed inhibitors against plasmin. Chem Pharm Bull (Tokyo) 1991;39:2340-2346.
107. Teno N, Wanaka K, Okada Y, Taguchi H, Okamoto U, Hijikata-Okunomiya A, Okamoto S. Development of active center-directed plasmin and plasma kallikrein inhibitors and studies on the structure-inhibitory activity relationship. Chem Pharm Bull (Tokyo) 1993;41:1079-1090.
108. Okada Y, Matsumoto Y, Tsuda Y, Tada M, Wanaka K, Hijikata-Okunomiya A, Okamoto S. Development of plasmin-selective inhibitors and studies of their structure-activity relationship. Chem Pharm Bull (Tokyo) 2000;48:184-193.
109. Okada Y, Tsuda Y, Tada M, Wanaka K, Okamoto U, Hijikata-Okunomiya A, Okamoto S. Development of potent and selective plasmin and plasma kallikrein inhibitors and studies on the structure-activity relationship. Chem Pharm Bull (Tokyo) 2000;48:1964-1972.
110. Tsuda Y, Tada M, Wanaka K, Okamoto U, Hijikata-Okunomiya A, Okamoto S, Okad Y. Structure-inhibitory activity relationship of plasmin and plasma kallikrein inhibitors. Chem Pharm Bull (Tokyo) 2001;49:1457-1463.
111. Sanders TC, Seto CT. 4-Heterocyclohexanone-based inhibitors of the serine protease plasmin. J Med Chem 1999;42:2969-2976.
112. Conroy JL, Sanders TC, Seto CT. Using the electrostatic field effect to design a new class of inhibitors for cysteine proteases. J Am Chem Soc 1997;119:4285-4291.
113. Xue F, Seto CT. A comparison of cyclohexanone and tetrahydro-4H-thiopyran-4-one 1, 1-dioxide as pharmacophores for the design of peptide-based inhibitors of the serine protease plasmin. J Org Chem 2005;70:8309-8321.
114. Abato P, Conroy JL, Seto CT. Combinatorial library of serine and cysteine protease inhibitors that interact with both the S and S' binding sites. J Med Chem 1999;42:4001-4009.
115. Abato P, Yuen CM, Cubanski JY, Seto CT. Inhibitors of plasmin that extend into both the S and S' binding sites: Cooperative interactions between S1 and S2. J Org Chem 2002;67:1184-1191.
116. Xue F, Seto CT. Selective inhibitors of the serine protease plasmin: Probing the S3 and S3' subsites using a combinatorial library. J Med Chem 2005;48:6908-6917.
117. Xue F, Seto CT. Structure-activity studies of cyclic ketone inhibitors of the serine protease plasmin: Design, synthesis, and biological activity. Bioorg Med Chem 2006;14:8467-8487.
118. Hervio LS, Coombs GS, Bergstrom RC, Trivedi K, Corey DR, Madison EL. Negative selectivity and the evolution of protease cascades: The specificity of plasmin for peptide and protein substrates. Chem Biol 2000;7:443-453.
119. Driggers EM, Hale SP, Lee J, Terrett NK. The exploration of macrocycles for drug discovery-an underexploited structural class. Nat Rev Drug Discov 2008;7:608-624.
120. Hamada Y, Shioiri T. Recent progress of the synthetic studies of biologically active marine cyclic peptides and depsipeptides. Chem Rev 2005;105:4441-4482.
121. Tyndall JD, Nall T, Fairlie DP. Proteases universally recognize beta strands in their active sites. Chem Rev 2005;105:973-999.
122. Loughlin WA, Tyndall JD, Glenn MP, Fairlie DP. Beta-strand mimetics. Chem Rev 2004;104:6085-6117.
123. Tyndall JD, Fairlie DP. Macrocycles mimic the extended peptide conformation recognized by aspartic, serine, cysteine and metallo proteases. Curr Med Chem 2001;8:893-907.
124. Xue F, Seto CT. Macrocyclic inhibitors for the serine protease plasmin. J Enzyme Inhib Med Chem 2009;24:779-794.
125. Saupe SM, Steinmetzer T. A new strategy for the development of highly potent and selective plasmin inhibitors. J Med Chem 2012;55:1171-1180.
126. Lecaille F, Kaleta J, Brömme D. Human and parasitic papain-like cysteine proteases: Their role in physiology and pathology and recent developments in inhibitor design. Chem Rev 2002;102:4459-4488.
127. Hedstrom L. Serine protease mechanism and specificity. Chem Rev 2002;102:4501-4524.
128. Teno N, Gohda K, Wanaka K, Sueda T, Tsuda Y. Identification of novel plasmin inhibitors possessing nitrile moiety as warhead. Bioorg Med Chem Lett 2011;21:6305-6309.
129. Teno N, Otsubo T, Gohda K, Wanaka K, Sueda T, Ikeda K, Hijikata-Okunomiya A, Tsuda Y. Synthesis and evaluation of tripeptidic plasmin inhibitors with nitrile as warhead. J Pept Sci 2012;18:620-625.
130. Dietrich W, Nicklisch S, Koster A, Spannagl M, Giersiefen H, van de Locht A. CU-2010-a novel small molecule protease inhibitor with antifibrinolytic and anticoagulant properties. Anesthesiology 2009;110:123-130.
131. Steinmetzer T, Schweinitz A, Stuerzebecher J, Steinmetzer P, Soffing A, Van de Locht A, Nicklisch S, Reichelt C, Ludwig F-A, Schulze A, Daghisch M, Heinicke J. Trypsin-like serine protease inhibitors, and their preparation and use. US Patent Application 20100022781, 2010.
132. Szabó G, Veres G, Radovits T, Haider H, Krieger N, Bährle S, Miesel-Gröschel C, Niklisch S, Karck M, van de Locht A. Effects of novel synthetic serine protease inhibitors on postoperative blood loss, coagulation parameters, and vascular relaxation after cardiac surgery. J Thorac Cardiovasc Surg 2010;139:181-188.
133. Szabó G, Veres G, Radovits T, Haider H, Krieger N, Bährle S, Niklisch S, Miesel-Gröschel C, van de Locht A, Karck M. The novel synthetic serine protease inhibitor CU-2010 dose-dependently reduces postoperative blood loss and improves postischemic recovery after cardiac surgery in a canine model. J Thorac Cardiovasc Surg 2010;139:732-740.
134. The Medicines Company Discontinues Phase 2b Trial of MDCO-2010. http://ir.themedicinescompany.com/phoenix.zhtml?c=122204&p=irol-newsArticle&ID=1741990&highlight=. (Accessed on09/25/2013).
135. Kim H, Szlam F, Tanaka KA, van de Locht A, Ogawa S, Levy JH. The effects of MDCO-2010, a serine protease inhibitor, on activated clotting time in blood obtained from volunteers and cardiac surgical patients. Anesth Analg 2012;115:244-252.
136. Matsuoka S, Futagami M, Ohno H, Imaki K, Okegawa T, Kawasaki A. Inhibitory effects of ONO-3307 on various proteases and tissue thromboplastin in vitro and on experimental thrombosis in vivo. Jpn J Pharmacol 1989;51:455-463.
137. Yoshikawa T, Takeda S, Naito Y, Kondo M. Protective effects of ONO-3307, a new synthetic protease inhibitor against experimental disseminated intravascular coagulation in rats. Thromb Res 1990;60:1-7.
138. Sobajima H, Hayakawa T, Kondo T, Shibata T, Kitagawa M, Sakai Y, Ishiguro H, Tanikawa M, Nakae Y. Effect of a new synthetic trypsin inhibitor on taurocholate-induced acute pancreatitis in rats. Pancreas 1993;8:240-277.
139. Hirano T, Manabe T, Tobe T. Cytoprotective effects of prostaglandins and a new potent protease inhibitor in acute pancreatitis. Am J Med Sci 1992;304:154-163.
140. Hirano T, Manabe T, Tobe T. Protection by a new synthetic protease inhibitor, ONO3307, of the rat exocrine pancreas during acute edematous pancreatitis induced by a supramaximal dose of caerulein in comparison with FOY007. Pharmacology 1992;45:107-116.
141. Yoo KS, Huh KR, Kim YJ, Kim KO, Park CH, Hahn T, Park SH, Kim JH, Park CK, Kwon YJ, Lehman GA. Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: A prospective, randomized, double-blind, controlled trial. Pancreas 2011; 40:181-186.
142. Maruyama Y, Yoshida H, Uchino S, Yokoyama K, Yamamoto H, Takinami M, Hosoya T. Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: A three-year retrospective cohort study. Int J Artif Organs 2011;34:571-576.
143. Ryu HG, Jung CW, Lee CS, Lee J. Nafamostat mesilate attenuates postreperfusion syndrome during liver transplantation. Am J Transplant 2011;11:977-983.
144. Werner J, Hartwig W, Hackert T, Kaiser H, Schmidt J, Gebhard MM, Büchler MW, Klar E. Multidrug strategies are effective in the treatment of severe experimental pancreatitis. Surgery 2012;151:372-381.
145. Miyagi S, Kawagishi N, Nakanishi W, Fujio A, Miyazawa K, Maida K, Kashiwadate T, Hara Y, Sekiguchi S, Ohuchi N, Satomi S. Risk factors for hepatic artery thrombosis after microsurgical vascular reconstruction in liver transplantation. Transplant Proc 2013;45:1994-1996.
146. Taenaka N, Shimada Y, Hirata T, Nishijima M, Yoshiya I. New approach to regional anticoagulation in hemodialysis using gabexate mesilate (FOY). Crit Care Med 1982;10:773-775.
147. Takahashi T, Suzukawa M, Akiyama M, Hatao K, Nakamura Y. Systemic AL amyloidosis with disseminated intravascular coagulation associated with hyperfibrinolysis. Int J Hematol 2008;87:371-374.
148. Nishiyama T, Kohno Y, Koishi K. Effects of antithrombin and gabexate mesilate on disseminated intravascular coagulation: A preliminary study. Am J Emerg Med 2012;30:1219-1223.
149. Zakharova E, Horvath MP, Goldenberg DP. Structure of a serine protease poised to resynthesize a peptide bond. Proc Natl Acad Sci USA 2009;106:11034-11039.
150. Radisky ES, Koshland DE, Jr. A clogged gutter mechanism for protease inhibitors. Proc Natl Acad Sci USA 2002;99:10316-10321.
151. Laskowski M, Jr, Kato I. Protein inhibitors of proteinases. Annu Rev Biochem 1980;49:593-626.
152. Laskowski M, Qasim MA. What can the structures of enzyme-inhibitor complexes tell us about the structures of enzyme substrate complexes? Biochim Biophys Acta 2000;1477:324-337.
153. Schechter I, Berger A. On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 1967;27:157-162.
154. Markland W, Ley AC, Lee SW, Ladner RC. Iterative optimization of high-affinity proteases inhibitors using phage display. 1. Plasmin. Biochemistry 1996;35:8045-8057.
155. Bajaj MS, Ogueli GI, Kumar Y, Vadivel K, Lawson G, Shanker S, Schmidt AE, Bajaj SP. Engineering kunitz domain 1 (KD1) of human tissue factor pathway inhibitor-2 to selectively inhibit fibrinolysis: Properties of KD1-L17R variant. J Biol Chem 2011;286:4329-4340.
156. Ascenzi P, Bocedi A, Bolognesi M, Spallarossa A, Coletta M, De Cristofaro R, Menegatti E. The bovine basic pancreatic trypsin inhibitor (Kunitz inhibitor): A milestone protein. Curr Protein Pept Sci 2003;4:231-251.
157. Kraut E, Frey EK, Werle E. About the inactivation of Kallikrein. (In German: Hoppe-Seyler Zeitschr). Physiol Chem 1930;192:1-21.
158. Kunitz M, Northrop JH. Isolation from beef pancreas of crystalline trypsinogen, trypsin, a trypsin inhibitor, and an inhibitor-trypsin compound. J Gen Physiol 1936;19:991-1007.
159. Chauvet J, Acher R. The reactive site of the basic trypsin in hibitor of pancreas. Role of lysine 15. J Biol Chem 1967;242:4274-4275.
160. Beckmann J, Mehlich A, Schröder W, Wenzel HR, Tschesche H. Preparation of chemically 'mutated' aprotinin homologues by semisynthesis. P1 substitutions change inhibitory specificity. Eur J Biochem 1988;176:675-682.
161. Beckmann J, Mehlich A, Schröder W, Wenzel HR, Tschesche H. Semisynthesis of Arg15, Glu15, Met15, and Nle15-aprotinin involving enzymatic peptide bond resynthesis. J Protein Chem 1989;8:101-113.
162. Groeger C, Wenzel HR, Tschesche H. Enzymatic semisynthesis of aprotinin homologues mutated in P' positions. J Protein Chem 1991;10:245-251.
163. Krowarsch D, Zakrzewska M, Smalas AO, Otlewski J. Structure-function relationships in serine protease-bovine pancreatic trypsin inhibitor interaction. Protein Pept Lett 2005;12:403-407.
164. Grzesiak A, Krokoszynska I, Krowarsch D, Buczek O, Dadlez M, Otlewski J. Inhibition of six serine proteinases of the human coagulation system by mutants of bovine pancreatic trypsin inhibitor. J Biol Chem 2000;275:33346-33352.
165. Otlewski J, Jaskólski M, Buczek O, Cierpicki T, Czapińska H, Krowarsch D, Smalas AO, Stachowiak D, Szpineta A, Dadlez M. Structure-function relationship of serine protease-protein inhibitor interaction. Acta Biochim Pol 2001;48:419-428.
166. Porte RJ, Leebeek FW. Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery. Drugs 2002;62:2193-2211.
167. Hendrickson JE, Hillyer CD. Noninfectious serious hazards of transfusion. Anesth Analg 2009;108:759-769.
168. Landis RC, Asimakopoulos G, Poullis M, Haskard DO, Taylor KM. The antithrombotic and antiinflammatory mechanisms of action of aprotinin. Ann Thorac Surg 2001;72:2169-2175.
169. Poston RS, White C, Gu J, Brown J, Gammie J, Pierson RN, Lee A, Connerney I, Avari T, Christenson R, Tandry U, Griffith BP. Aprotinin shows both hemostatic and antithrombotic effects during off-pump coronary artery bypass grafting. Ann Thorac Surg 2006;81:104-110.
170. Asimakopoulos G, Thompson R, Nourshargh S, Lidington EA, Mason JC, Ratnatunga CP, Haskard DO, Taylor KM, Landis RC. An anti-inflammatory property of aprotinin detected at the level of leukocyte extravasation. J Thorac Cardiovasc Surg 2000;120:361-369.
171. Sperzel M, Huetter J. Evaluation of aprotinin and tranexamic acid in different in vitro and in vivo models of fibrinolysis, coagulation and thrombus formation. J Thromb Haemost 2007;5:2113-2118.
172. Ray M, Hatcher S, Whitehouse S L, Crawford S, Crawford R. Aprotinin and epsilon aminocaproic acid are effective in reducing blood loss after primary total hip arthroplasty-a prospective randomized double-blind placebo-controlled study. J Thromb Haemost 2005;3:1421-1427.
173. Yang IS, Kim TG, Park BS, Cho KJ, Lee JH, Park Y, Kim KH. Crystal structures of aprotinin and its complex with sucrose octasulfate reveal multiple modes of interactions with implications for heparin binding. Biochem Biophys Res Commun 2010;397:429-435.
174. Lindahl U, Feingold DS, Roden L. Biosynthesis of heparin. Trends Biochem Sci 1986;11:221-225.
175. Rivera V, Levieux A, Levieux D. Characterisation of Ag1, the major speciesspecific contaminant of bovine crude heparin, and its identification as an aprotinin/heparin complex. J Pharm Biomed Anal 2002;29:443-458.
176. Kestin AS, Valeri CR, Khuri SF, Loscalzo J, Ellis PA, MacGregor H, Birjiniuk V, Ouimet H, Pasche B, Nelson MJ. The platelet function defect of cardiopulmonary bypass. Blood 1993;82:107-117.
177. John LC, Rees GM, Kovacs IB. Reduction of heparin binding to and inhibition of platelets by aprotinin. Ann Thorac Surg 1993;55:1175-1179.
178. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. New Engl J Med 2006;354:353-365.
179. Schneeweiss S, Seeger JD, Landon J, Walker AM. Aprotinin during coronary-artery bypass grafting and risk of death. New Engl J Med 2008;358:771-783.
180. Henry DA, Carless PA, Moxey AJ, O'Connell D, Stokes BJ, Fergusson DA, Ker K. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2011;3:CD001886.
181. Mangano DT, Miao Y, Vuylsteke A, Tudor IC, Juneja R, Filipescu D, Hoeft A, Fontes ML, Hillel Z, Ott E, Titov T, Dietzel C, Levin J. Investigators of the multicenter study of perioperative ischemia research group; Ischemia Research and Education Foundation. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 2007;97:471-479.
182. Shaw AD, Stafford-Smith M, White WD, Phillips-Bute B, Swaminathan M, Milano C, Welsby IJ, Aronson S, Mathew JP, Peterson ED, Newman MF. The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med 2008;358:784-793.
183. Cosgrove DM 3rd, Heric B, Lytle BW, Taylor PC, Novoa R, Golding LA, Stewart RW, McCarthy PM, Loop FD. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg 1992;54:1031-1036.
184. Dietrich W, Ebell A, Busley R, Boulesteix AL. Aprotinin and anaphylaxis: analysis of 12, 403 exposures to aprotinin in cardiac surgery. Ann Thorac Surg 2007;84:1144-1150.
185. Howell N, Senanayake E, Freemantle N, Pagano D. Putting the record straight on aprotinin as safe and effective: Results from a mixed treatment meta-analysis of trials of aprotinin. J Thorac Cardiovasc Surg 2013;145:234-240.
186. Beckerman Z, Shopen Y, Alon H, Cohen O, Nir RR, Adler Z, Bolotin G. Coronary artery bypass grafting after aprotinin: Are we doing better? J Thorac Cardiovasc Surg 2013;145:243-248.
187. Sniecinski RM, Karkouti K, Levy JH. Managing clotting: A North American perspective. Curr Opin Anaesthesiol 2012;25:74-79.
188. Petersen LC, Bjørn SE, Norris F, Norris K, Sprecher C, Foster DC. Expression, purification and characterization of a Kunitz-type protease inhibitor domain from human amyloid precursor protein homolog. FEBS Lett 1994;338:53-57.
189. Navaneetham D, Wu W, Li H, Sinha D, Tuma RF, Walsh PN. P1 and P2' site mutations convert protease nexin-2 from a factor XIa inhibitor to a plasmin inhibitor. J Biochem 2013;153:221-231.
190. Kong D, Ma D, Bai H, Guo H, Cai X, Mo W, Tang Q, Song H. Expression and characterization of the first kunitz domain of human tissue factor pathway inhibitor-2. Biochem Biophys Res Commun 2004;324:1179-1185.
191. Petersen LC, Bjørn SE, Olsen OH, Nordfang O, Norris F, Norris K. Inhibitory properties of separate recombinant Kunitz-type-protease-inhibitor domains from tissue-factor-pathway inhibitor. Eur J Biochem 1996;235:310-316.
192. Marlor CW, Delaria KA, Davis G, Muller DK, Greve JM, Tamburini PP. Identification and cloning of human placental bikunin, a novel serine protease inhibitor containing two Kunitz domains. J Biol Chem 1997;272:12202-12208.
193. Delaria KA, Muller DK, Marlor CW, Brown JE, Das, RC, Roczniak SO, Tamburini PP. Characterization of placental bikunin, a novel human serine protease inhibitor. J Biol Chem 1997;272:12209-12214.
194. Oliva ML, Souza-Pinto JC, Batista IF, Araujo MS, Silveira VF, Auerswald EA, Mentele R, Eckerskorn C, Sampaio MU, Sampaio CA. Leucaena leucocephala serine proteinase inhibitor: Primary structure and action on blood coagulation, kinin release and rat paw edema. Biochim Biophys Acta 2000;1477:64-74.
195. Paesen GC, Siebold C, Harlos K, Peacey MF, Nuttall PA, Stuart DI. A tick protein with a modified Kunitz fold inhibits human tryptase. J Mol Biol 2007;368:1172-1186.
196. Masci PP, Whitaker AN, Sparrow LG, de Jersey J, Winzor DJ, Watters DJ, Lavin MF, Gaffney PJ. Textilinins from Pseudonaja textilis. Characterization of two plasmin inhibitors that reduce bleeding in an animal model. Blood Coagul Fibrinolysis 2000;11:385-393.
197. Filippovich I, Sorokina N, Masci PP, de Jersey J, Whitaker AN, Winzor DJ, Gaffney PJ, Lavin MF. A family of textilinin genes, two of which encode proteins with antihaemorrhagic properties. Br J Haematol 2002;119:376-384.
198. Flight S, Johnson L, Trabi M, Gaffney P, Lavin M, de Jersey J, Masci P. Comparison of textilinin-1 with aprotinin as serine protease inhibitors and as antifibrinolytic agents. Pathophysiol. Haemost Thromb 2005;34:188-193.
199. Flight SM, Johnson LA, Du QS, Warner RL, Trabi M, Gaffney PJ, Lavin MF, de Jersey J, Masci PP. Textilinin-1, an alternative anti-bleeding agent to aprotinin: Importance of plasmin inhibition in controlling blood loss. Br J Haematol 2009;145:207-211.
200. Millers EK, Trabi M, Masci PP, Lavin MF, de Jersey J, Guddat LW. Crystal structure of textilinin-1, a Kunitz-type serine protease inhibitor from the venom of the Australian common brown snake (Pseudonaja textilis). FEBS J 2009;276:3163-3175.
201. Millers EK, Johnson LA, Birrell GW, Masci PP, Lavin MF, de Jersey J, Guddat LW. The structure of human microplasmin in complex with textilinin-1, an aprotinin-like inhibitor from the Australian brown snake. PLoS ONE 2013;8:e54104.
202. Earl ST, Masci PP, de Jersey J, Lavin MF, Dixon J. Drug development from Australian elapid snake venoms and the Venomics pipeline of candidates for haemostasis: Textilinin-1 (Q8008), Haempatch™ (Q8009) and CoVase™ (V0801). Toxicon 2012;59:456-463.
203. Wan H, Lee KS, Kim BY, Zou FM, Yoon HJ, Je YH, Li J, Jin BR. A spider-derived Kunitz-type serine protease inhibitor that acts as a plasmin inhibitor and an elastase inhibitor. PLoS ONE 2013;8:e53343.
204. Cheng AC, Tsai IH. Functional characterization of a slow and tight-binding inhibitor of plasmin isolated from Russell's viper venom. Biochim Biophys Acta 2014;1840:153-159.
205. Qiu Y, Lee KS, Choo YM, Kong D, Yoon HJ, Jin BR. Molecular cloning and antifibrinolytic activity of a serine protease inhibitor from bumblebee (Bombus terrestris) venom. Toxicon 2013;63:1-6.
206. Choo YM, Lee KS, Yoon HJ, Qiu Y, Wan H, Sohn MR, Sohn HD, Jin BR. Antifibrinolytic role of a bee venom serine protease inhibitor that acts as a plasmin inhibitor. PLoS ONE 2012;7:e32269.
207. Valdés JJ, Schwarz A, Cabeza de Vaca I, Calvo E, Pedra JH, Guallar V, Kotsyfakis M. Tryptogalinin is a tick Kunitz serine protease inhibitor with a unique intrinsic disorder. PLoS ONE 2013;8:e62562.
208. Rimphanitchayakit V, Tassanakajon A. Structure and function of invertebrate Kazal-type serine proteinase inhibitors. Dev Comp Immunol 2010;34:377-386.
209. Ranasinghe S, McManus DP. Structure and function of invertebrate Kunitz serine protease inhibitors. Dev Comp Immunol 2013;39:219-227.
210. Campos IT, Amino R, Sampaio CA, Auerswald EA, Friedrich T, Lemaire HG, Schenkman S, Tanaka AS. Infestin, a thrombin inhibitor presents in Triatoma infestans midgut, a Chagas' disease vector: Gene cloning, expression and characterization of the inhibitor. Insect Biochem Mol Biol 2002;32:991-997.
211. Lovato DV, Nicolau de Campos IT, Amino R, Tanaka AS. The full-length cDNA of anticoagulant protein infestin revealed a novel releasable Kazal domain, a neutrophil elastase inhibitor lacking anticoagulant activity. Biochimie 2006;88:673-681.
212. Campos IT, Tanaka-Azevedo AM, Tanaka AS. Identification and characterization of a novel factor XIIa inhibitor in the hematophagous insect, Triatoma infestans (Hemiptera: Reduviidae). FEBS Lett 2004;577:512-516.
213. Campos IT, Souza TA, Torquato RJ, De Marco R, Tanaka-Azevedo AM, Tanaka AS, Barbosa J. A. The Kazal-type inhibitors infestins 1 and 4 differ in specificity but are similar in three-dimensional structure. Acta Crystallogr D Biol Crystallogr 2012;68:695-702.
214. Chen JW, Figueiredo JL, Wojtkiewicz GR, Siegel C, Iwamoto Y, Kim DE, Nolte MW, Dickneite G, Weissleder R, Nahrendorf M. Selective factor XIIa inhibition attenuates silent brain ischemia: Application of molecular imaging targeting coagulation pathway. JACC Cardiovasc Imaging 2012;5:1127-1138.
215. Kim YH, Choi JG, Lee GM, Kang KW. Domain and genomic sequence analysis of bdellin-KL, a leech-derived trypsin-plasmin inhibitor. J Biochem 2001;130:431-438.
216. Kubiak A, Jakimowicz P, Polanowski A. A Kazal-type serine proteinase inhibitor from chicken liver (clTI-1): Purification, primary structure, and inhibitory properties. Int J Biol Macromol 2009;45:194-199.
217. Lopuska A, Polanowska J, Wilusz T, Polanowski A. Purification of two low-molecular-mass serine proteinase inhibitors from chicken liver. J Chromatogr A 1999;852:207-216.
218. Watanabe RM, Tanaka-Azevedo AM, Araujo MS, Juliano MA, Tanaka AS. Characterization of thrombin inhibitory mechanism of rAaTI, a Kazal-type inhibitor from Aedes aegypti with anticoagulant activity. Biochimie 2011;93:618-623.
219. Watanabe RM, Soares TS, Morais-Zani K, Tanaka-Azevedo AM, Maciel C, Capurro ML, Torquato RJ, Tanaka AS. A novel trypsin Kazal-type inhibitor from Aedes aegypti with thrombin coagulant inhibitory activity. Biochimie 2010;92:933-939.
220. Sugino H, Nakagawa S, Kakinuma A. Plasminostreptin, a protein proteinase inhibitor produced by Streptomyces antifibrinolyticus. II. Determination of the reactive site for proteinases. J Biol Chem 1978;253:1538-1545.
221. Kakinuma A, Sugino H, Moriya N, Isono M. Plasminostreptin, a protein proteinase inhibitor produced by Streptomyces antifibrinolyticus. I. Isolation and characterization. J Biol Chem 1978;253:1529-1537.
222. Wu W, Li H, Navaneetham D, Reichenbach ZW, Tuma RF, Walsh PN. The kunitz protease inhibitor domain of protease nexin-2 inhibits factor XIa and murine carotid artery and middle cerebral artery thrombosis. Blood 2012;120:671-677.
223. Salameh MA, Soares AS, Hockla A, Radisky DC, Radisky ES. The P(2)' residue is a key determinant of mesotrypsin specificity: Engineering a high-affinity inhibitor with anticancer activity. Biochem J 2011;440:95-105.
224. Fukushima T, Kawaguchi M, Yamasaki M, Tanaka H, Yorita K, Kataoka H. Hepatocyte growth factor activator inhibitor type 1 suppresses metastatic pulmonary colonization of pancreatic carcinoma cells. Cancer Sci 2011;102:407-413.
225. Lehmann A. Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery. Expert Opin Biol Ther 2008;8:1187-1199.
226. Devy L, Rabbani SA, Stochl M, Ruskowski M, Mackie I, Naa L, Toews M, van Gool R, Chen J, Ley A, Ladner RC, Dransfield DT, Henderikx P. PEGylated DX-1000: Pharmacokinetics and antineoplastic activity of a specific plasmin inhibitor. Neoplasia 2007;9:927-937.
227. Ranasinghe S, McManus DP. Structure and function of invertebrate Kunitz serine protease inhibitors. Dev Comp Immunol 2013;39:219-227.
228. Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JP, Broze GJ, Jr. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 1989;338:518-520.
229. Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 2001;86:959-972.
230. Chand HS, Schmidt AE, Bajaj SP, Kisiel W. Structure-function analysis of the reactive site in the first Kunitz-type domain of human tissue factor pathway inhibitor-2. J Biol Chem 2004;279:17500-17507.
231. Murkin JM, Falter F, Granton J, Young B, Burt C, Chu M. High-dose tranexamic acid is associated with nonischemic clinical seizures in cardiac surgical patients. Anesth Analg 2010;110:350-353.
232. Scott CJ, Taggart CC. Biologic protease inhibitors as novel therapeutic agents. Biochimie 2010 92:1681-1688.
233. Bokesch PM, Szabo G, Wojdyga R, Grocott HP, Smith PK, Mazer CD, Vetticaden S, Wheeler A, Levy JH. A phase 2 prospective, randomized, double-blind trial comparing the effects of tranexamic acid with ecallantide on blood loss from high-risk cardiac surgery with cardiopulmonary bypass (CONSERV-2 Trial). J Thorac Cardiovasc Surg 2012 143:1022-1029.
234. Gandhi NS, Mancera RL.The structure of glycosaminoglycans and their interactions with proteins. Chem Biol Drug Des 2008;72:455-482.
235. Chander A, Atkinson HM, Stevic I, Berry LR, Kim PY, Chan AK. Interactions of heparin and a covalently-linked antithrombin-heparin complex with components of the fibrinolytic system. Thromb Haemost 2013;110:1180-1188.
236. Highsmith RF, Rosenberg RD. The inhibition of human plasmin by human antithrombin-heparin cofactor. J Biol Chem 1974;249:4335-4338.
237. Machovich R, Bauer PI, Arányi P, Kecskés E, Büki KG, Horváth I. Kinetic analysis of the heparin-enhanced plasmin-antithrombin III reaction. Apparent catalytic role of heparin. Biochem J 1981;199:521-526.
238. Smith GF, Sundboom JL. Heparin and protease inhibition. II. The role of heparin in the ATIII inactivation of thrombin, plasmin, and trypsin. Thromb Res 1981;22:115-133.
239. Jordan RE, Oosta GM, Gardner WT, Rosenberg RD. The binding of low molecular weight heparin to hemostatic enzymes. J Biol Chem 1980;255:10073-10080.
240. Yomtova VM, Stambolieva NA, Blagoev, BM. Kinetic study of the effect of heparin on the amidase activity of trypsin, plasmin and urokinase. Thromb Haemost 1983;49:199-203.
241. Bauer PI, Pozsgay M, Machovich R, Elödi P, Horváth I. The interaction of heparin with human plasmin. Int J Biochem 1983;15:871-874.
242. Higazi AA, Aziza R, Samara AA, Mayer M. Regulation of fibrinolysis by non-esterified fatty acids. Biochem J 1994;300:251-255.
243. Higazi AA, Finci-Yeheskel Z, Samara AA, Aziza R, Mayer M. Stimulation of plasmin activity by oleic acid. Biochem J 1992;282:863-866.
244. Legras S, Diczhazi C, Moczar M. N-oleoyl heparin inhibits the amidolytic activity of plasmin and urokinase. Int J Biol Macromol 1992;14:97-99.
245. Henry BL, Abdel Aziz M, Zhou Q, Desai UR. Sulfated, low-molecular-weight lignins are potent inhibitorsof plasmin, in addition to thrombin and factor Xa: Novel opportunity for controlling complex pathologies. Thromb Haemost 2010;103:507-515.
246. Ledoux D, Papy-Garcia D, Escartin Q, Sagot MA, Cao Y, Barritault D, Courtois J, Hornebeck W, Caruelle JP. Human plasmin enzymatic activity is inhibited by chemically modified dextrans. J Biol Chem 2000;275:29383-29390.
247. Vörös G, Kolev K, Csomor K, Machovich R. Inhibition of plasmin activity by sulfated polyvinylalcohol-acrylate copolymers. Thromb Res 2000;100:353-361.
248. Monien BH, Henry BL, Raghuraman A, Hindle M, Desai UR. Novel chemo-enzymatic oligomers of cinnamic acids as direct and indirect inhibitors of coagulation proteinases. Bioorg Med Chem 2006;14:7988-7998.
249. Henry BL, Monien BH, Bock PE, Desai UR. A novel allosteric pathway of thrombin inhibition: Exosite II mediated potent inhibition of thrombin by chemo-enzymatic, sulfated dehydropolymers of 4-hydroxycinnamic acids. J Biol Chem 2007;282:31891-1899.
250. Henry BL, Thakkar JN, Martin EJ, Brophy DF, Desai UR. Characterization of the plasma and blood anticoagulant potential of structurally and mechanistically novel oligomers of 4-hydroxycinnamic acids. Blood Coagul Fibrinolysis 2009;20:27-34.
251. Henry BL, Thakkar JN, Liang A, Desai UR. Sulfated, low molecular weight lignins inhibit a select group of heparin-binding serine proteases. Biochem Biophys Res Commun 2012;417:382-386.
252. Abdel Aziz MH, Mosier PD, Desai UR. Identification of the site of binding of sulfated, low molecular weight lignins on thrombin. Biochem Biophys Res Commun 2011;413:348-352.
253. Snyder KM, Kessler CM. The pivotal role of thrombin in cancer biology and tumorigenesis. Semin Thromb Hemost 2008;34:734-741.
254. Churg A, Wright JL. Proteases and emphysema. Curr Opin Pulm Med 2005;11:153-159.
255. Saluja B, Thakkar JN, Li H, Desai UR, Sakagami M. Novel low molecular weight lignins as potential anti-emphysema agents: In vitro triple inhibitory activity against elastase, oxidation and inflammation. Pulm Pharmacol Ther 2013;26:296-304.
256. Meddahi A, Benoit J, Ayoub N, Sézeur A, Barritault D. Heparin-like polymers derived from dextran enhances colonic anastomosis resistance to leakage. J Biomed Mater Res 1996;31, 293-297.
257. Tardieu M, Gamby C, Avramoglou T, Jozefonvicz J, Barritault D. Derivatized dextrans mimic heparin as stabilizers, potentiators, and protectors of acidic or basic FGF. J Cell Physiol 1992;150:194-203.
258. Meddahi A, Lemdjabar H, Caruelle JP, Barritault D, Hornebeck W. FGF protection and inhibition of human neutrophil elastase by carboxymethyl benzylamide sulfonate dextran derivatives. Int J Biol Macromol 1996;18:141-135.
259. Meddahi A, Blanquaert F, Saffar JL, Colombier ML, Caruelle JP, Josefonvicz J, Barritault, D. New approaches to tissue regeneration and repair. Pathol Res Pract 1994;190:923-928.
260. Blanquaert F, Saffar JL, Colombier ML, Carpentier G, Barritault D. Caruelle JP. Heparan-like molecules induce the repair of skull defects. Bone 1995;17:499-506.
261. Fredj-Reygrobellet D, Hriskova DL, Ettaiche M, Meddahi A, Jozefonwicz J, Barritault, D. CMDBS, functional analog of heparin sulfate as a new class of corneal ulcer healing agents. Ophtalmic Res 1994;26:325-331.
262. Desgranges P, Barbaud C, Caruelle JP, Barritault D, Gautron J. A substituted dextran enhances muscle fiber survival and regeneration in ischemic and denervated rat EDL muscle. FASEB J 1999;13:761-766.
263. Machovich R, Nagy M, Györgyi-Edelenyi J, Csomor K, Horvath I. Anticoagulant effect of sulphated polyvinylalcohol-acrylic acid copolymers. Thromb Haemost 1986;56:397-400.
264. Wanaka K, Okamoto S, Horie N, Hijikata-Okunomiya A, Okamoto U, Naito T, Ohno N, Bohgaki M, Tsuda Y, Okada Y. Use of an active center-directed plasmin inhibitor elucidates the multiplicity of plasmin actions. Thromb Res 1996;82:79-86.
265. Lee E, Enomoto R, Takemura K, Tsuda Y, Okada Y. A selective plasmin inhibitor, trans-aminomethylcyclohexanecarbonyl-L-(O-picolyl)tyrosine-octylamide (YO-2), induces thymocyte apoptosis. Biochem Pharmacol 2002;63:1315-1323.
266. Enomoto R, Sugahara C, Komai T, Suzuki C, Kinoshita N, Hosoda A, Yoshikawa A, Tsuda Y, Okada Y, Lee E. The structure-activity relationship of various YO compounds, novel plasmin inhibitors, in the apoptosis induction. Biochim Biophys Acta 2004;1674:291-298.
267. Szende B, Okada Y, Tsuda Y, Horvath A, Bökönyi G, Okamoto S, Wanaka K, Kéri G. A novel plasmin-inhibitor inhibits the growth of human tumor xenografts and decreases metastasis number. In Vivo 2002;16:281-286.
268. Goodloe JM, Howerton DS, McAnallen D, Reed H. TXA: A difference-maker for trauma patients. JEMS 2013;38:60-65.
269. Roberts I, Shakur H, Coats T, Hunt B, Balogun E, Barnetson L, Cook L, Kawahara T, Perel P, Prieto-Merino D, Ramos M, Cairns J, Guerriero C. The CRASH-2 trial: A randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technol Assess 2013;17:1-79.
270. Reichel CA, Lerchenberger M, Uhl B, Rehberg M, Berberich N, Zahler S, Wymann MP, Krombach F. Plasmin inhibitors prevent leukocyte accumulation and remodeling events in the postischemic microvasculature. PLoS ONE 2011;6:e17229.
271. Tse TW, Hui E. Tranexamic acid: An important adjuvant in the treatment of melasma. J Cosmet Dermatol 2013;12:57-66.
272. Takahashi H, Tatewaki W, Wada K, Yoshikawa A, Shibata A. Thrombin and plasmin generation in patients with liver disease. Am J Hematol 1989;32:30-35.
273. Stürzebecher J, Vieweg H, Steinmetzer T, Schweinitz A, Stubbs MT, Renatus M, Wikström P. 3-Amidinophenylalanine-based inhibitors of urokinase. Bioorg Med Chem Lett 1999;9:3147-3152.
274. Froriep D, Clement B, Bittner F, Mendel RR, Reichmann D, Schmalix W, Havemeyer A. Activation of the anti-cancer agent upamostat by the mARC enzyme system. Xenobiotica 2013;43:780-784.
275. Ertongur S, Lang S, Mack B, Wosikowski K, Muehlenweg B, Gires O. Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system. Int J Cancer 2004;110:815-824.
276. Setyono-Han B, Stürzebecher J, Schmalix WA, Muehlenweg B, Sieuwerts AM, Timmermans M, Magdolen V, Schmitt M, Klijn JG, Foekens JA. Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1. Thromb Haemost 2005;93:779-786.
277. Heinemann V, Ebert MP, Laubender RP, Bevan P, Mala C, Boeck S. Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer. Br J Cancer 2013;108:766-770.
278. Gustafsson D, Antonsson T, Bylund R, Eriksson U, Gyzander E, Nilsson I, Elg M, Mattsson C, Deinum J, Pehrsson S, Karlsson O, Nilsson A, Sörensen H. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost 1998;79:110-118.
279. Mannucci PM, Levi M. Prevention and treatment of major blood loss. New Engl J Med 2007;356:2301-2311.
280. Koster A, Schirmer U. Re-evaluation of the role of antifibrinolytic therapy with lysine analogs during cardiac surgery in the post aprotinin era. Curr Opin Anaesthesiol 2011;24:92-97.
281. Sander M, Spies CD, Martiny V, Rosenthal C, Wernecke KD, von Heymann C. Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: A retrospective analysis. Crit Care 2010;14:R148.
282. Furtmueller R, Schlag MG, Berger M, Hopf R, Huck S, Sieghart W, Redl H. Tranexamic acid, a widely used antifibrinolytic agent, causes convulsions by a gamma-aminobutyric acid(A) receptor antagonistic effect. J Pharmacol Exp Ther 2002;301:168-173.
283. Al-Horani RA, Liang A, Desai UR. Designing nonsaccharide, allosteric activators of antithrombin for accelerated inhibition of factor Xa. J Med Chem 2011;54:6125-6138.
284. Karuturi R, Al-Horani RA, Mehta SC, Gailani D, Desai UR. Discovery of allosteric modulators of factor XIa by targeting hydrophobic domains adjacent to its heparin-binding site. J Med Chem 2013;56:2415-2428.
285. Al-Horani RA, Ponnusamy P, Mehta AY, Gailani D, Desai UR. Sulfated penta-galloylglucoside is a potent, allosteric, and selective inhibitor of factor XIa. J Med Chem 2013;56:867-878.
286. Abdel Aziz MH, Sidhu PS, Liang A, Kim JY, Mosier PD, Zhou Q, Farrell DH, Desai UR. Designing allosteric regulators of thrombin. Monosulfated benzofuran dimers selectively interact with Arg173 of exosite 2 to induce inhibition. J Med Chem 2012;55:6888-6897.
287. Sidhu PS, Abdel Aziz MH, Sarkar A, Mehta AY, Zhou Q, Desai UR. Designing allosteric regulators of thrombin. Exosite 2 features multiple subsites that can be targeted by sulfated small molecules for inducing inhibition. J Med Chem 2013;56:5059-5070.
288. Desai UR. The promise of sulfated synthetic small molecules as modulators of glycosaminoglycan function. Future Med Chem 2013;5:1363-1366.